Navigation Links
Santaris Pharma Presents Positive Clinical Data on SPC2996 in,Chronic Lymphocytic Leukaemia

r cell death and removal without resorting to chemotherapy.

About SPC2966

SPC2996 is the first of a portfolio of novel experimental drugs blocking harmful gene expression being designed and developed by Santaris Pharma. The drug belongs to a new class of drugs called RNA Antagonists, proprietary to Santaris Pharma, based on the novel three-dimensional analogue of RNA known as Locked Nucleic Acid (LNA). The drug binds with high potency and specificity to the messenger RNA for Bcl-2 and destroys it within the cell, resulting in a reduction in Bcl-2 protein concentration. SPC2996 is an investigational product which has not yet been approved by any regulatory agency as effective or safe for patient use but the novel agent is currently being evaluated in international Phase I/II studies in human CLL in centres in Denmark, France, UK and the USA.

About Santaris Pharma

Santaris Pharma is a clinical-stage biopharmaceutical company focused on developing a new class of drugs intended to switch off the expression of harmful genes. Called RNA Antagonists, these new drugs are being developed by Santaris and its corporate partners for the treatment of cancer and metabolic disorders. Created in May 2003 and backed by a broad group of leading international life science venture capital investors, Santaris Pharma completed a Euro 40m second round of equity financing in May 2006. In July 2006, the Company entered into a global partnership with Enzon Pharmaceuticals of New Jersey to co-develop and commercialise a series of Santaris RNA Antagonists for improving the treatment of cancer.

Santaris Pharma's RNA Antagonist drug pipeline is based on its unique LNA technology. LNA drugs, with their high potency and biostability, have the potential to transform the field of RNAi medicines, making specific and effective gene silencing a reality in human medicine. If this potential is realised, even in part, it may be possible to design new drugs to treat the u
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Santaris Pharma presents positive preclinical data on SPC2996 at the American Association for Cancer Research
2. Sygnis Pharma AG announces date for presentation of clinical results
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
(Date:1/8/2009)...to Identify and Validate Novel Gene Expression Bio...Gene Expression Platform , , FREMONT, Calif., J...s, Inc. (OTC Bulletin Board: WGBS), a leading deve...ing, cell biology and stem cell research systems, ...ation with the University of Texas Southwestern M...
(Date:1/8/2009)... at the initial dose in an ongoing Phase Ib trial ... after three days , , Conference Call Today at ...irstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq:...ohort of an ongoing Phase Ib clinical trial of ANA...polymerase inhibitor. ANA598 was very well-tolera...
(Date:1/7/2009)...ants Drive the Increase , , WHITE PLAINS, N.Y.,...statistics confirm that the decades-long rise in t...ting more infants than ever at increased risk of d...s. , , Nearly 543,000 babies were born too soon...lth Statistics, which today released "Births: Fina...
(Date:1/7/2009)... Tiantan Puhua Hospital Stem Cells ...dwide leader in using stem cells to effectively tr...w globally experienced additions to its medical an...pital,s treatment capabilities for growing numbers...r doctors include the distinguished Dr. Jiang Ping...
Breaking Medicine Technology:WaferGen and University of Texas Southwestern Medical Center Establish Biomarker Research Collaboration for SmartChip(TM) Real-Time PCR System 2WaferGen and University of Texas Southwestern Medical Center Establish Biomarker Research Collaboration for SmartChip(TM) Real-Time PCR System 3WaferGen and University of Texas Southwestern Medical Center Establish Biomarker Research Collaboration for SmartChip(TM) Real-Time PCR System 4WaferGen and University of Texas Southwestern Medical Center Establish Biomarker Research Collaboration for SmartChip(TM) Real-Time PCR System 5ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 2ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 3ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 4ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 5ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 6Preterm Births Rise 36 Percent Since Early 1980s 2Stem Cell Treatment Leader Tiantan Puhua Adds Experienced International Medical Staff for Expanding Numbers of Patients 2Stem Cell Treatment Leader Tiantan Puhua Adds Experienced International Medical Staff for Expanding Numbers of Patients 3Male cyclists risk sexual problems if they don 26 23146 3Bt choose the right bike 3937 1Male cyclists risk sexual problems if they don 26 23146 3Bt choose the right bike 3937 2Mitigating Medical Identity Theft 3A AHIMA Journal Provides Patient Tools to Secure Health Information 23459 1Mitigating Medical Identity Theft 3A AHIMA Journal Provides Patient Tools to Secure Health Information 23459 2Mitigating Medical Identity Theft 3A AHIMA Journal Provides Patient Tools to Secure Health Information 23459 3Johnson 26 Johnson to Host Analyst Conference Call on Second Quarter Results 23454 1RADI Medical Systems Launches Next Generation PressureWire 28R 29 Certus 6415 1RADI Medical Systems Launches Next Generation PressureWire 28R 29 Certus 6415 2
...l results from a,Phase II study presented for the ...annual meeting showed that MK-0974, an,investigati...eceptor antagonist, significantly improved migrain...lacebo, and the relief was,sustained through 24 ho...tudy. Responses specific to other measures, such a...
...irstCall/ --,Mymetics Corporation announced today ...,s HIV vaccine elicited neutralizing,IgA mucosal a...A,antibodies are considered as a possible first li...ere presented by Sylvain,Fleury, Ph.D., Mymetics, ...titled, "Without Mucosal Adjuvant, Virosomes-gp41,...
Other Medicine Technology:Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study 2Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study 3Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study 4Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study 5Mymetics' HIV Vaccine Demonstrates First-Ever Production of,Neutralizing IgA Antibodies in Non-Human Primate Model 2Mymetics' HIV Vaccine Demonstrates First-Ever Production of,Neutralizing IgA Antibodies in Non-Human Primate Model 3Mymetics' HIV Vaccine Demonstrates First-Ever Production of,Neutralizing IgA Antibodies in Non-Human Primate Model 4
(Date:1/9/2009)...re/ -- , - New Online Service Provides the ...s at Whatever Age , A new website has been ...esigned specifically to get rid of all examination...AID and it can be found at, http://www.befreefrom...struction, there and then, on how to get rid of ex...
(Date:1/8/2009)...art risk may not be accurate in some cases , ...udies, from the United States and the Netherlands,...lished Framingham Risk Score in predicting heart d...am score, based on findings of a decades-long stud...to assess risk on the basis of seven factors: age,...
(Date:1/8/2009)...rganizations offers five action steps to improve r...wswire/ -- Despite the recent three-hour cease fir...ies to residents of the Palestinian territory, upw...clean water and medical help. U.S.-based internati... region see this arrangement to allow sporadic del...
(Date:1/8/2009)... Daschle at his confirmation hearing to be the nex..., WASHINGTON, Jan. 8 Bi... Senator Tom Daschle, nominee for Department of He...by fellow BPC founder and friend Senator Bob Dole ... convened by the Senate Health, Education, Labor, ...
Breaking Medicine News(10 mins):Health News:Be Free From Exam Nerves 2Health News:Studies Challenge Framingham Risk Score 2Health News:Studies Challenge Framingham Risk Score 3Health News:Temporary Cease Fires Not Enough for Humanitarian Aid Groups Working in Gaza 2Health News:Temporary Cease Fires Not Enough for Humanitarian Aid Groups Working in Gaza 3Health News:Bipartisan Policy Center Founding Board Members Daschle and Dole Appear on Capitol Hill 2Health News:Bipartisan Policy Center Founding Board Members Daschle and Dole Appear on Capitol Hill 3Health News:Bipartisan Policy Center Founding Board Members Daschle and Dole Appear on Capitol Hill 4
...can reduce infant mortality rates, the Centre has ...mpaigns on breast feeding on the lines of the init...alone can reduce infant mortality rates by 13 per ...r the child but also ensures a strong foundation f...
...the Bhopal Gas Tragedy continuesto haunt the publi...six more victims dead from the 1984 Bhopal gas tra...re to treat the affectedpeople are being accused o...e than six people have died in the past two months...
... called NFATc1 tends to cause massive bone accumul...osis //- HHMI investigator Gerald Crabtree and HHM...rtebrates, bone is constantly being formed and bei...lled osteoclasts continuously degrade bone, while ...
...he issue of Archives of General Psychiatry, it is ...der the age of 20, being treated with antipsychoti...cs are medications used to treat mental disorders,...may involve loss of contact with reality. Several ...
Other Medicine News:Health News:Six More Bhopal Gas Tragedy Continues to Take Toll 2Health News:Osteoporosis – A New Treatmen 2Health News:Osteoporosis – A New Treatmen 3Health News:Number of Children, Teens Being Treated for Mental Disorders is on Rise 2
Fixed chair back and armrests, electric lift with 8" (20.3cm) stroke, foot pedal control, choice of upholstery colors. Optional features: 15 tilt mechanism and footrest, locking rotation, sliding arm
Complete with headrest, armrests, footrest and foot switch.
...Large hinged footstep can support patient's full w...ired. Hydraulic base. Patients may be raised and l...chair back or optional corded foot switch. Dual ro... to swivel the chair 330 without changing position...
Heine Beta 200 Streak Retinoscope 3.5v w/Twist Lock for Welch-Allyn style handles.
Medicine Products: